Maraviroc intensification of cART in patients with suboptimal immunological recovery: a 48-week, placebo-controlled randomized trial

MLA

Steven Van lelyveld, et al. Maraviroc Intensification of CART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial. 2015. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.ocn947616674&authtype=sso&custid=ns315887.

APA

Steven Van lelyveld, Julia Drylewicz, Maaike Krikke, Ellen Veel, Sigrid Otto, Clemens Richter, Robin Soetekouw, Jan Prins, Kees Brinkman, Jan Willem Mulder, Frank Kroon, Ananja Middel, Jori Symons, Annemarie Wensing, Monique Nijhuis, Jose Borghans, Kiki Tesselaar, & Andy Hoepelman. (2015). Maraviroc intensification of cART in patients with suboptimal immunological recovery: a 48-week, placebo-controlled randomized trial.

Chicago

Steven Van lelyveld, Julia Drylewicz, Maaike Krikke, Ellen Veel, Sigrid Otto, Clemens Richter, Robin Soetekouw, et al. 2015. “Maraviroc Intensification of CART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.ocn947616674&authtype=sso&custid=ns315887.